Phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in previously untreated, unresected stage IIIB-IV melanoma. (7th November 2013) - Puzanov, Igor; Milhem, Mohammed; Andtbacka, Robert; Minor, David; Hamid, Omid; Li, Ai; VanderWalde, Ari; Kaufman, Howard